Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;7(Suppl 2):S165-S170.
doi: 10.21037/tlcr.2018.03.19.

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer

Vanesa Gregorc  1 , Chiara Lazzari  1 , Niki Karachaliou  2 , Rafael Rosell  3   4 , Mariacarmela Santarpia  5
Affiliations
Editorial

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer

Vanesa Gregorc et al. Transl Lung Cancer Res. 2018 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Treatment algorithm of EGFR-mutated NSCLC patients. Patients with baseline EGFR-activating mutations and pre-treatment EGFR T790M in the future could receive osimertinib up-front. Those patients carrying EGFR-activating mutations only can be treated with first- or second-generation EGFR-TKIs or osimertinib up-front. At the time of radiological progression after first- or second-generation EGFR-TKIs, patients should undergo liquid biopsy to define the molecular mechanisms of acquired resistance. In the presence of EGFR T790M, osimertinib is the recommended option. In case of EGFR T790M negative, it is mandatory to perform tissue re-biopsy. At the time of radiological progression after osimertinib, liquid biopsy should be performed to search for the presence of C797S. In case of C797S in cis with T790M, chemotherapy is the recommended options, while in the presence of C797S in trans with T790M, a combination of osimertinib with first- or second-generation EGFR-TKIs could be an option. EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; NSCLC, non-small cell lung cancer.
See this image and copyright information in PMC

Comment on

  • Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Soria JC, et al. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Clinical Trial.

References

    1. Torre LA, Siegel RL, Ward EM, et al. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev 2016;25:16-27. 10.1158/1055-9965.EPI-15-0578 - DOI - PubMed
    1. Santarpia M, Karachaliou N, Rosell R. Beyond platinum treatment for NSCLC: what does the future hold? Expert Rev Anticancer Ther 2017;17:293-5. 10.1080/14737140.2017.1288103 - DOI - PubMed
    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. 10.1056/NEJMoa040938 - DOI - PubMed
    1. Leveque D. Pharmacokinetics of gefitinib and erlotinib. Lancet Oncol 2011;12:1093. 10.1016/S1470-2045(11)70306-0 - DOI - PubMed
    1. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11. 10.1038/onc.2008.109 - DOI - PMC - PubMed